Globe on Big Pharma R&D Failure
3 Comments
Recent Posts
Tech Exodus: Why Bill C-22’s Privacy and Security Risks Will Drive Digital Services Out of the Country 
The Lawful Access Two-Headed Surveillance Monster: How Bill C-22 Went Off the Rails 
How Much Further Will Lawful Access Go?: Police Chief Tells Bill C-22 Hearing That Three Years of Metadata Retention Would Be “Ideal” 
Bill C-22’s Groundhog Day: Why the Government’s Dismissal of Signal, Apple and the U.S. Congress Concerns Runs Back the Disastrous Online News Act Playbook 
Slick Videos Won’t Save Lawful Access: Why The Government’s Bill C-22 Defence Avoids the Charter, Privacy and Security Concerns Raised By Critics
So, repeal C-22
If the drug companies can renege, then so can the goodies that were given to them be taken away.
Seems pretty straightforward to me.
Why aren’t there such things as charitable venture capital orgs? After-all many charities (eg JDRC) contribute to for-profit orgs. It seems to me that charitable donations would go much further if the beneficiaries of donations (R&D orgs) had to contribute returns back to charities. The role of charities like JDRC then would be to encourage R&D firms to take greater risks.
Hey, Michael! Don’t be so ungrateful or narrow minded. What about the bevy of busy lawyers who make gazillions every year doing “research” on their endless litany of pharmaceutical patent cases in the courts? What about all that useful literature and education directed at the medical profession, so that they are better informed about what pills their patients should pop? That takes a lot of “research and development”. And what about all the consumer focus group “research†that goes into those cute Cialis TV commercials?